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Swi5 and Ace2 are cell cycle-regulated transcription
factors that activate expression of early G1-specific
genes in Saccharomyces cerevisiae. Swi5 and Ace2 have
zinc finger DNA-binding domains that are highly con-
served, and the two proteins bind to the same DNA se-
quences in vitro. Despite this similarity in DNA binding,
Swi5 and Ace2 activate different genes in vivo, with Swi5
activating the HO gene and Ace2 activating CTS1 ex-
pression. In this report we have used chimeric fusions
between Swi5 and Ace2 to determine what regions of
these proteins are necessary for promoter-specific acti-
vation of HO and CTS1. We have identified specific re-
gions of Swi5 and Ace2 that are required for activation
of HO and CTS1, respectively. The Swi5 protein binds
HO promoter DNA cooperatively with the Pho2 home-
odomain protein, and the HO specificity region of Swi5
identified in the chimeric analysis coincides with the
region of Swi5 previously identified that interacts with
Pho2 in vitro. Swi5 and Ace2 also activate expression of
a number of other genes expressed in G1 phase of the cell
cycle, including ASH1, CDC6, EGT2, PCL2, PCL9, RME1,
and SIC1. Analysis of the Swi5/Ace2 chimeras shows that
distinct regions of Swi5 and Ace2 contribute to the tran-
scriptional activation of some of these other G1-regu-
lated genes.
How do transcription factors of the same DNA-binding class
activate specific target genes? This problem, called promoter-
specific activation, can be explained by several simple mecha-
nisms involving differential DNA binding, subcellular localiza-
tion of related transcription factors, or the timing of expression
of those factors. The zinc finger DNA-binding transcription
factors Swi5 and Ace2 bind to the same sequences in vitro with
approximately the same affinity, yet in vivo they activate dis-
tinct genes (1, 2). Swi5 activates transcription of the HO gene,
encoding the site-specific endonuclease required for mating
type switching (3). Ace2 activates CTS1, which encodes chiti-
nase, required to degrade the cell wall between mother and
daughter cells to complete cytokinesis (2). Both CTS1 and HO
are expressed in late G1 of the cell cycle, while SWI5 and ACE2
genes are transcribed in late G2 (2, 4). When these factors are
translated during G2, both proteins are retained in the cyto-
plasm. At the end of mitosis, the transcription factors enter the
nucleus and are subsequently degraded after activating their
gene targets (2, 5). Although the timing of entry into the nu-
cleus for both proteins has not been determined simulta-
neously, it is clear that the times of nuclear entry are very
close. In addition, the nuclear localization sequence for Swi5
has been mapped, and this region is conserved between Swi5
and Ace2, making it unlikely that there are large differences in
their nuclear localization patterns (2, 5).
The Swi5 and Ace2 proteins show similarity at the amino
acid level, as shown in Fig. 1. The two proteins are almost
identical in the zinc finger DNA-binding domain region, with
83% identity, rising to 94% with conservative amino acid sub-
stitutions. The amino acids predicted to make nucleotide-spe-
cific contacts with DNA, based on the Zif268 zinc finger pro-
tein/DNA co-crystal (6), are highly conserved between Ace2 and
Swi5, leading to the prediction that these two proteins would
recognize the same DNA sequences (2). In vitro DNA-binding
experiments with both truncated proteins expressed in Esche-
richia coli and full-length proteins produced in rabbit reticulo-
cyte lysates demonstrated that Swi5 and Ace2 do in fact bind to
HO and CTS1 promoter sequences with similar affinity (1, 7).
However, the N-terminal regions of Swi5 and Ace2 (520 and
570 amino acids, respectively, are poorly conserved, with 18%
identity through this region. There are, however, three small
blocks of similarity, ranging from 20 to 27 amino acids each, in
this large N-terminal region (Fig. 1).
In addition to HO and CTS1, Swi5 and Ace2 also activate
transcription of the ASH1, CDC6, EGT2, RME1, SIC1, PCL2,
and PCL9 genes (8–15). These genes encode a diverse set of
proteins (Table I), but a common feature is that all of these
genes are expressed in early G1 phase of the cell cycle. The
Swi5 and Ace2 proteins are present in the nucleus for a limited
time in early G1 and are thus G1-specific transcription factors.
The role of Swi5 and Ace2 in the activation of these G1 genes is
complex. For some of these target genes, either Swi5 or Ace2 is
competent for activation, while for other genes Swi5 is the
primary activator with only a minor role for Ace2. We describe
these genes as being “jointly” regulated by Swi5 and Ace2, to
distinguish their regulation from that of HO and CTS1, where
only one of the zinc finger proteins is an effective transcrip-
tional activator. Therefore, promoter-specific activation by
Swi5 and Ace2 cannot be explained by a simple mechanism,
inasmuch as, at some target genes, Swi5 and Ace2 appear
equivalent for transcriptional activation.
We expect that specific domains within the Swi5 and Ace2
proteins are involved in promoter-specific activation of HO and
CTS1. Both positive and negative factors determine the ability
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of Swi5 and Ace2 to activate HO and CTS1 (1, 16–18), and
presumably these transcription factors interact with Swi5 and
Ace2. For example, Swi5 binds to the HO promoter coopera-
tively with another factor, the Pho2 homeodomain protein (17).
Ace2 does not interact with Pho2 (1), and thus the interaction
of Swi5 with Pho2 may contribute to the specific activation of
HO. Similarly, we have identified negative regulators that
prevent Swi5 from activating CTS1 expression (1). In this
paper, we describe the identification of regions for both the
Swi5 and Ace2 proteins that are responsible for promoter-
specific activation of HO and CTS1, respectively. In addition,
we show that particular regions of Swi5 and Ace2 contribute to
the activation of some of the jointly regulated genes. These
results are a first step toward understanding the mechanism of
promoter-specific activation by the Swi5 and Ace2 transcrip-
tion factors.
EXPERIMENTAL PROCEDURES
Plasmids—Plasmids used in this study are listed in Table II. Recom-
binant PCR1 was used to generate all chimeric fragments, which were
then cloned into YCplac33. The end points of the fusion are indicated in
Table II by the amino acid end points of the fusions. Primer and
template sequences will be provided upon request. The YIp plasmids
M3319–M3325 were generated by replacing a PvuI fragment in YI-
plac211 with a PvuI fragment containing the chimera from the appro-
priate YCp plasmid. The CTS1 (46)-lacZ reporter plasmid M2864 has
been described previously (1). The HIS4-lacZ plasmid M2296 was con-
structed by moving a 5-kilobase pair SalI fragment with HIS4-lacZ
from plasmid pLL54 (19) into a Bluescript derivative containing TRP1;
this plasmid was the gift of Yi Wei Jiang.
Yeast Strains—Saccharomyces cerevisiae strains are listed in Table
III. Strains DY150, DY411, DY1142, DY1143, and DY1148 have been
described previously (2). The CTS1-lacZ reporter integrated at the
LEU2 locus in DY1897 has been described (1). Strains DY4497–DY4503
are derived from DY1143 by integrating plasmids M3319–M3325, re-
spectively, at the URA3 locus after digestion with StuI. C-terminal 13
Myc epitope tags were added as described by Longtine et al. (20) using
PCR products generated using plasmid pFA6a:13MycKanMX6 as tem-
plate. Oligonucleotides F665 (59-AATGGAACGGGGATTATGGTTTCG-
CCAATGAAAACTAATCAAAGGCGGATCCCCGGGTTAATTAA-39)
and F666 (59-TGTTACCCACATTCTCCACTCTTCCACAGAAAAAATT-
CCTAAAGTGAATTCGAGCTCGTTTAAAC-39) were used to tag the C
terminus of Swi5, and oligonucleotides F667 (59-GAGCAAAACTCGA-
ACCGCACCCTTTCAAACGAAACTGATGCTCTCCGGATCCCCGGG-
TTAATTAA-39) and F668 (59- GGCCCTTAAGACTACAGTGTACGTA-
AATCGTAAAGAAATAAATGTGAATTCGAGCTCGTTTAAAC-39) were
used to tag the C terminus of Ace2.
Quantitation of RNA Levels—RNA measurements were made by S1
protection assays as described (21) using RNA isolated from 200 ml of
YEPD cultures harvested at an OD660 5 0.5. All samples were sonicated
for 5 s before the OD660 was measured to compensate for OD differences
between clumpy and nonclumpy strains. The following oligonucleotides
were used: ASH1 (59-GCCTTGGGACGCACAGGTGAGGATGATCTTG-
ATCTCATCTTGCCACTTTTCGTCGGTGTGAGAAAG-39), CDC6 (59-C-
ATTCAGATCTTGGAAGGAATCGAAAATCTTCTGGAAAATGGAGG-
ACGGCTCTCCCAACGGCGCGT-39), CMD1 (59-GGGCAAAGGCTTCT-
TTGAATTCAGCAATTTGTTCTTCGGTGGAGGC-39), CTS1 (59-CGCA-
AAATCAATGTCTGCATTTTCCAACAAGTCACCAACAGAAGCATCC-
GGGTATGGACATTGTGGTGCGATGAGG-39), EGT2 (59- CCGCTACT-
CAATGATGCAGTAACCGCAACTTCAGGGATAGCGGATGATTGCG-
AAGTATAAGAAGAAAGCGGGTCCG-39), HO (59-GCCCTGTGTGAC-
ATTTATGACGCGGGCAGCGGAGCCATCTGCGCACATAACGTAAG-
AGTTAGCCCACCGC-39), PCL2 (59-GATAAATTCGATCTTCTAGATT-
CCAACGTGGAGAGGGTCGAAGTGGAAGCTAAAGATGGGCGCTCA-
39), PCL9 (59-GGATGTCAGTGAAGGAACCGATATAGCAGAAGAAGT-
TCTAGAATGCGAAACCGGTCTTCTGCAGCC-39), RME1 (59-GGGAC-
ACTTACACGGTCTTTCAAGGTTGAATTCGTCTAAGTGCGCGGCAA-
ACTCAACTAACGTTGCGAACCCCCTG-39), and SIC1 (59-CGACCCA-
ATGGTTCCTGCTCTTCCCTTACTGTTCCATTATCATGACTTTCAAA-
TTGGAATAGTGTCCTCTGACAGT-39). Quantitative analysis was
performed using ImageQuant software and a Molecular Dynamics
PhosphorImager. Radioactivity in each lane was measured, the backg-
round level was subtracted, and the value was normalized by dividing
by the value for the CMD1 internal control.
Quantitative determinations of b-galactosidase activity were per-
formed as described previously (22). Each value is the average of four
independent transformants. Western blots were performed with 9E10
anti-Myc monoclonal antibody and ECL Western kit (Amersham Phar-
macia Biotech).
RESULTS
Identification of HO and CTS1 Specificity Regions of Swi5
and Ace2—In order to identify what regions of Swi5 and Ace2
contribute to promoter-specific activation of HO and CTS1, we
generated chimeric fusions between Swi5 and Ace2. In a pre-
vious report we described Swi5/Ace2 chimeras that were cre-
ated by exchanging restriction fragments (2). In particular, the
Swi5-(1–538)/Ace2-(591–770) chimera was unable to activate
either HO or CTS1 (2). Due to the insertion of an oligonucleo-
tide linker with a restriction site, this particular chimera has a
two-amino acid insertion in a region highly conserved between
Swi5 and Ace2. An NMR structural analysis of the DNA-bind-
ing domain of Swi5 has recently shown that these two extra
nucleotides are part of an a-helical region that contributes to
the stability of the first zinc finger of Swi5 (23). Thus, the
failure of this Swi5-(1–538)/Ace2-(591–770) chimera to activate
either HO or CTS1 can be attributed to perturbation of the
protein structure.
We therefore made more precise fusions using recombinant
PCR. We were concerned that the fusion junction between two
proteins would affect protein secondary structure, and decided
to use the regions of homology shown in Fig. 1 as locations for
fusions. This method of generating the chimeras proved much
more successful in that all the fusions were active at least one
of the transcriptional reporters tested. In addition, the chime-
ras activated transcription to the degree of either wild type
Swi5 or Ace2, indicating that not only are the proteins ex-
pressed, but perhaps more importantly, that they are
functional.
Chimeric constructs were cloned into YCp vectors. The chi-
meras were expressed from either the SWI5 or ACE2 promot-
ers, depending on what protein fragment is N-terminal. Using
the regions of similarity as a guide, Swi5 and Ace2 were broken
into six parts, designated A, B, C, D, E, and F. Region E
contains the DNA-binding domain, and region F contains the
nuclear localization and cytoplasmic retention sequences. This
nomenclature will be used throughout this paper to indicate
what protein domains a chimeric fusion contains. For example,
ABCDSwi5EFAce2 contains regions A, B, C, and D from Swi5 and
regions E and F from Ace2.
The chimeric fusions between Swi5 and Ace2 were analyzed
for their ability to activate HO-lacZ or CTS1-lacZ reporter.
YCp plasmids with the chimeric fusions were transformed into
yeast strains that lacked endogenous Ace2 and Swi5, and that
contained an integrated HO-lacZ or a CTS1-lacZ reporter.
Promoter activity was quantitated by measuring b-galactosid-
ase levels, and are shown as a percentage of either the level of
activation that Swi5 gives at HO-lacZ or that Ace2 gives at
CTS1-lacZ (Fig. 2).
The first set of chimeras show that the DNA-binding domain1 The abbreviation used is: PCR, polymerase chain reaction.
TABLE I
Genes jointly regulated by Swi5 and Ace2
Gene Function
ASH1 Daughter specific repressor of HO expression
CDC6 Initiator of DNA replication
EGT2 Required for cell separation
PCL2 Partner for Pho85 cyclin-dependent kinase
PCL9 Partner for Pho85 cyclin-dependent kinase
RME1 Repressor of meiosis; activator of CLN2 transcription
SIC1 Inhibitor of Cdc28 cyclin-dependent kinase
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does not determine promoter specificity at HO and CTS1. Chi-
meras ABCDAce2EFSwi5 and ABCDSwi5EFAce2 (Fig. 2, lines 3
and 4) were constructed with regions E and F, containing the
DNA-binding domain of one transcriptional activator, fused to
regions A–D of the other. The results show clearly that the
N-terminal part of the proteins, regions A–D, confer promoter-
specific activation. Swi5 and Ace2 proteins bind in vitro to HO
or CTS1 promoter fragments with similar affinities (1), and
thus it was not unexpected that the DNA-binding domains of
Swi5 and Ace2 are not the critical determinants of promoter-
specific activation. Region F, which controls the regulated nu-
clear entry of Swi5, is highly conserved between Swi5 and
Ace2. Since Swi5 and Ace2 enter the nucleus at similar times
(2, 24), this region was not expected to be critical for promoter
specificity.
What regions within A–D are important for promoter-spe-
cific activation? To address this question, additional chimeric
fusion proteins were generated. Chimera ABCAce2DEFSwi5
(Fig. 2, line 5) is able to activate HO-lacZ, while ABCDAce2-
EFSwi5 (Fig. 2, line 4) cannot. These results suggest that region
D of Swi5 (amino acids 394–521) is necessary for activation of
the HO-lacZ reporter, and we designate this region the HO
specificity region. This region of Swi5 has been also shown to be
necessary for interaction of Swi5 with the Pho2 homeodomain
protein (25, 26).
The next set of chimeras suggest that region C of Ace2 is
required for specific activation of CTS1. Chimera
ABCAce2DEFSwi5 (Fig. 2, line 5) can activate CTS1-lacZ, while
ABAce2CDEFSwi5 (Fig. 2, line 7) cannot, and the difference
between these two constructs is the presence of region C of
Ace2. An additional chimera was constructed to test whether
region C of Ace2 is sufficient for CTS1 activation in the context
of the Swi5 protein. The ABSwi5CAce2DEFSwi5 chimera can ac-
tivate HO-lacZ, due to the presence of region D from Swi5, and
it can also activate CTS1-lacZ (Fig. 3). We have designated
region C of Ace2 (amino acids 303–469) as the CTS1 specificity
region. A fusion protein consisting of the lexA DNA-binding
domain fused to region C of Ace2 is a strong activator of a
transcriptional reporter containing lexA binding sites in the
CYC1 promoter (data not shown). This result demonstrates
that region C contains a transcriptional activation domain
capable of activating transcription from the CYC1 TATA
element.
The ABCSwi5DEFAce2 chimera is not able to activate either
HO-lacZ or CTS1-lacZ (Fig. 2, line 6), raising the concern that
this protein is not functional or stable in vivo. We used two
other reporter constructs that can be activated by either Swi5
or Ace2 to determine whether ABCSwi5DEFAce2 is functional.
The CTS1 (46)-lacZ reporter, which contains the Ace2 binding
sites but lacks the negative regulatory site that blocks activa-
tion by Swi5, is inactive in a swi5 ace2 double mutant (1), but
TABLE II
Plasmids
YCpac33 YCp plasmid with URA3 marker
M2292 YCplac33 with SWI5 in YCplac33
M2297 YCplac33 with ACE2 in YCplac33
M2452 YCplac33 with ABCDSwi5EFAce2 expressed from SWI5 promoter; Swi5-(1–521)-Ace2-(576–770)
M2474 YCplac33 with ABCDAce2EFSwi5 expressed from ACE2 promoter; Ace2-(1–575)-Swi5-(522–709)
M2552 YCplac33 with ABCAce2DEFSwi5 expressed from ACE2 promoter; Ace2-(1–469)-Swi5-(394–709)
M2253 YCplac33 with ABCSwi5DEFAce2 expressed from SWI5 promoter; Swi5-(1–393)-Ace2-(470–770)
M2849 YCplac33 with ABAce2CDEFSwi5 expressed from ACE2 promoter; Ace2-(1–301)-Swi5-(260–709)
M2850 YCplac33 with ABSwi5CDEFAce2 expressed from SWI5 promoter; Swi5-(1–259)-Ace2-(302–770)
M2866 YCplac33 with ABSwi5CAce2DEFSwi5 expressed from SWI5 promoter; Swi5-(1–259)-Ace2-(302–469)-Swi5(394–709)
YIplac211 YIp plasmid with URA3 marker
M3319 YIplac211 with ABCDSwi5EFAce2 expressed from SWI5 promoter
M3320 YIplac211 with ABCDAce2EFSwi5 expressed from ACE2 promoter
M3321 YIplac211 with ABCAce2DEFSwi5 expressed from ACE2 promoter
M3322 YIplac211 with ABCSwi5DEFAce2 expressed from SWI5 promoter
M3323 YIplac211 with ABAce2CDEFSwi5 expressed from ACE2 promoter
M3324 YIplac211 with ABSwi5CDEFAce2 expressed from SWI5 promoter
M3325 YIplac211 with ABSwi5CAce2DEFSwi5 expressed from SWI5 promoter
M2864 CTS1 promoter (2560 to 2515) inserted into CYC1(TATA)-lacZ reporter in YEp plasmid with TRP1 marker
M2296 HIS4-lacZ reporter in YRp plasmid with TRP1 marker
TABLE III
Yeast strains
All strains are in the W303 strain background (29) except DY1148, which is a K1107 strain (30).
DY150 MATa ade2 can1 his3 leu2 trp1 ura3
DY411 MATa swi5<hisG ade2 can1 his3 leu2 trp1 ura3
DY1142 MATa ace2<HIS3 ade2 can1 his3 leu2 trp1 ura3
DY1143 MATa swi5<hisG ace2<HIS3 ade2 can1 his3 leu2 trp1 ura3
DY1148 MATa HO-lacZ swi5<TRP1 ace2<HIS3 ade2 ade6 can1 his3 leu2 met trp1 ura3
DY1897 MATa LEU2<CTS1-lacZ swi5<hisG ace2<HIS3 ade2 can1 his3 leu2 trp1 ura3
DY4497 MATa swi5<hisG ace2<HIS3 URA3<ABCDSwi5EFAce2 ade2 can1 his3 leu2 trp1
DY4498 MATa swi5<hisG ace2<HIS3 URA3<ABCDAce2EFSwi5 ade2 can1 his3 leu2 trp1
DY4499 MATa swi5<hisG ace2<HIS3 URA3<ABCAce2DEFSwi5 ade2 can1 his3 leu2 trp1
DY4500 MATa swi5<hisG ace2<HIS3 URA3<ABCSwi5DEFAce2 ade2 can1 his3 leu2 trp1
DY4501 MATa swi5<hisG ace2<HIS3 URA3<ABAce2CDEFSwi5 ade2 can1 his3 leu2 trp1
DY4502 MATa swi5<hisG ace2<HIS3 URA3<ABSwi5CDEFAce2 ade2 can1 his3 leu2 trp1
DY4503 MATa swi5<hisG ace2<HIS3 URA3<ABSwi5CAce2DEFSwi5 ade2 can1 his3 leu2 trp1
FIG. 1. The Swi5 and Ace2 transcription factors are similar at
the amino acid level. In addition to the zinc finger region, there are
five segments of similarity between Swi5 and Ace2. The regions A–D,
between the similar segments, are not conserved.
Promoter-specific Activation Domains of Swi5 and Ace2 21031
can be activated by either Swi5 or Ace2 (Fig. 4). The HIS4-lacZ
reporter responds similarly to either Swi5 or Ace2 (Fig. 4; Ref.
7). The ABCSwi5DEFAce2 chimera is able to activate both CTS1
(46)-lacZ and HIS4-lacZ equivalently to full-length Swi5, indi-
cating that this chimeric fusion is functional in vivo. To directly
determine levels of the chimeric proteins in vivo, we generated
strains with a Myc epitope fused in frame at the C terminus of
Ace2, Swi5, and each of the chimeras. Western analysis shows
that the fusion proteins are expressed at similar levels as the
wild type Ace2 and Swi5 proteins (Fig. 5). Although the
ABCSwi5DEFAce2 chimera (lane 7) is expressed at slightly lower
levels than other chimeras, it is expressed at a level similar to
that of native Swi5 (lane 2). We conclude that the reason the
ABCSwi5DEFAce2 chimera is unable to activate HO-lacZ and
CTS1-lacZ is because it lacks a promoter specificity domain
from either Swi5 or Ace2.
We used an S1 nuclease protection assay of mRNA levels to
measure the ability of the various chimeras to activate tran-
scription of the native HO and CTS1 genes in strains generated
by integrating the various chimeric fusions at the URA3 locus
of a swi5 ace2 double mutant strain. The rationale for this
experiment is twofold. First, we have observed differences in
regulatory properties of the integrated HO-lacZ reporter com-
pared with the native HO locus (18, 27). Second, we have also
noted subtle differences in regulation of the jointly regulated
genes (i.e. SIC1) when YCp plasmids with SWI5 and ACE2
were used compared with integrated genes (data not shown).
We attribute this difference to the slightly higher copy number
of YCp plasmids compared with single copy integrants. The
pattern of activation by the different chimeras at the endoge-
nous HO and CTS1 genes was similar to that seen for the lacZ
reporters (Fig. 6).
G1 Genes Activated by Swi5 and Ace2—There are a number
of genes expressed in early G1 whose expression has been
reported to be activated by Swi5 or Ace2 (Table I). RNA was
isolated from four isogenic strains differing at the SWI5 and
ACE2 loci and used for S1 nuclease protection analysis using
probes specific for each of these seven genes. The experiment
was performed three times, and the average values are pre-
sented in Table IV. All of these genes show a significant reduc-
tion in expression in the swi5 ace2 double mutant. However,
none of them show a reduction as strong as that seen for HO
and CTS1 in either the swi5 or ace2 single mutants. For con-
venience, we have designated these as jointly regulated genes.
These genes show varying dependence on Swi5 and Ace2 for
transcriptional activation. For example, either Swi5 or Ace2
can activate ASH1, EGT2, RME1, or PCL2 as expression is
only modestly reduced in the swi5 and ace2 single mutants, but
is significantly reduced in the swi5 ace2 double mutant. Reduc-
tion in mRNA levels in the swi5 ace2 double mutant is more
substantial for EGT2 and RME1 than for ASH1 or PCL2. In
contrast, Swi5 is the major activator of SIC1 and PCL9 expres-
sion, but we note that expression of SIC1 and PCL9 is further
reduced in the swi5 ace2 double mutant. Swi5 also plays the
major role in activation of CDC6, as an ace2 mutation has little
effect. Although CDC6 expression is not decreased by an ace2
mutation, we discuss the regulatory properties of CDC6 with
the jointly regulated genes because its expression is only par-
tially reduced by a swi5 mutation. It has been shown that the
Swi4/Swi6 transcription factors, along with Swi5, activate
CDC6 (9), and thus there is a high residual level of CDC6
expression in the swi5 ace2 double mutant.
Activation of Jointly Regulated Genes by Swi5-Ace2 Chimeric
Fusions—We examined the ability of the chimeric fusions be-
tween Swi5 and Ace2 shown in Fig. 2 to activate transcription
of the jointly regulated genes (ASH1, CDC6, EGT2, PCL2,
FIG. 2. Activation of the HO-lacZ
and CTS1-lacZ reporters by the Swi5/
Ace2 chimeric proteins. YCp plasmids
expressing chimeric fusions between Swi5
and Ace2 were transformed into yeast
strains and grown in medium lacking ura-
cil, and extracts were prepared for b-ga-
lactosidase assays. Four independent
transformants were assayed; standard
deviations were less than 20%. The chi-
mera diagrams, which are not to scale,
have regions A–F labeled with Swi5 se-
quences in black and Ace2 sequences in
gray. The DNA-binding domain, region E,
is shown as a stippled block. Footnote a,
expression of the integrated HO-lacZ re-
porter in DY1148 (ace2 swi5) is given as a
percentage normalized to the Swi5 con-
trol (line 2); footnote b, expression of the
integrated CTS1-lacZ reporter in DY1897
(ace2 swi5) is given as a percentage nor-
malized to the Ace2 control (line 1).
FIG. 3. Region C from Ace2 is sufficient to confer CTS1-lacZ activation upon Swi5. YCp plasmids expressing chimeric fusions between
Swi5 and Ace2 were transformed into yeast strains and grown in medium lacking uracil, and extracts were prepared for b-galactosidase assays.
Four independent transformants were assayed, and standard deviations were less than 20%. Chimera diagrams are as in Fig. 2. Footnote a,
expression of the integrated HO-lacZ reporter in DY1148 (ace2 swi5) is given as a percentage normalized to the Swi5 control (line 2); footnote b,
expression of the integrated CTS1-lacZ reporter in DY1897 (ace2 swi5) is given as a percentage normalized to the Ace2 control (line 1).
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PCL9, RME1, and SIC1). RNA was prepared from swi5 ace2
strains containing integrated versions of the chimeric fusions,
and mRNA levels were determined by S1 nuclease protection
with probes specific for each of the jointly regulated genes. This
experiment was performed three times, and mRNA levels were
quantitated by PhosphorImager analysis. Our results indicate
that, although the regions identified as required for HO and
CTS1 activation are in fact necessary for discrimination be-
tween those genes, they also contribute to activation of the
jointly regulated genes.
Analysis of activation of EGT2, PCL2, and ASH1 by the
chimeras did not identify any particular region of either Swi5
or Ace2 as critical for their activation (data not shown). This
means that almost all of the chimeric fusions analyzed were
capable of activating expression of these genes. This suggests
that either protein can contribute to gene activation equally,
and that no one region of Swi5 or Ace2 is required for expres-
sion of these genes. This is consistent with a model in which
promoter-specific activation is distinct from activation at pro-
moters where Swi5 and Ace2 are equivalent. In contrast, the
C-terminal regions of Swi5 and Ace2, containing the DNA-
binding domains and nuclear localization sequences, are in-
volved in the activation of several of the jointly regulated
genes.
SIC1 and PCL9—SIC1 and PCL9 show very similar profiles
of activation by the different chimeras (Fig. 7). These genes are
primarily activated by Swi5, and the pattern seen for chimera
activation is very similar to that seen for HO (Figs. 2 and 6), in
that all chimeras with region D of Swi5 can activate SIC1 and
PCL9. However the ABCDAce2EFSwi5 chimera (Fig. 7, line 6),
which does not activate HO expression, does drive transcrip-
tion of SIC1 and PCL9. This chimera contains region EF from
Swi5, and indeed, all chimeras with region EF from Swi5 can
activate SIC1 and PCL9. Thus, either region D or region EF of
Swi5 is required for activation of these genes, indicating that
there are multiple regions within Swi5 involved in activation of
SIC1 and PCL9.
Chimeras ABCAce2DEFSwi5 (Fig. 7, line 7) and ABSwi5CAce2-
DEFSwi5 (Fig. 7, line 11) activate SIC1 and PCL9 well beyond the
wild type expression level. Along with region DEF of Swi5, which is
required for SIC1 and PCL9 expression, these chimeras also con-
tain region C from Ace2, the CTS1 specificity region. Region C of
Ace2 does not effectively activate these genes without region D and
region EF of Swi5 (i.e. in wild type Ace2, line 2). As described above,
region C from Ace2 contains an activation domain when targeted to
a heterologous promoter, and it is possible that it is this generalized
activation domain in region C that further stimulates the activity of
these two chimeras.
RME1—The RME1 gene shows an equal dependence on both
Swi5 and Ace2, as RME1 expression is reduced to similar
extents in the swi5 and ace2 single mutants but strongly re-
duced in the double mutant (Fig. 8A). These characteristics
distinguish it from the other jointly regulated genes. The pat-
tern of chimera activation of RME1 is similar to that seen for
HO, SIC1, and PCL9, as chimeras with region D of Swi5 can
activate RME1 expression well (lines 5, 7, 9, and 11). There are
some subtle differences, however. First, ABCDSwi5EFAce2 (line
5) activates RME1 much more effectively than full-length Swi5,
surpassing the amount of activation seen in the wild type
strain. This suggests that region EF of Ace2 contributes some
activation potential at RME1. An alternative explanation is
that region ABCD of Ace2 contains an inhibitory activity that
ABCD of Swi5 lacks. The reciprocal chimera, ABCDAce2EFSwi5
(line 6), activates similar to the level seen for full-length Ace2.
These results differ from that seen at SIC1 and PCL9, where
both the ABCDAce2EFSwi5 and ABCDSwi5EFAce2 (lines 5 and 6)
FIG. 4. Chimera ABCSwi5DEFAce2 is functional for transcriptional activation. Yeast strains were transformed with YCp plasmids
expressing chimeric fusions between Swi5 and Ace2 and, for a and b, also transformed with lacZ reporter plasmids. Transformants were grown
in medium lacking uracil or uracil and tryptophan to select for plasmids, and extracts were prepared for b-galactosidase assays. Four independent
transformants were assayed, and standard deviations were less than 30%. Footnote a, expression of the CTS1(46)-lacZ reporter on plasmid M2894
in strain DY1143 (ace2 swi5) is given as a percentage normalized to the Ace2 control (line 1); footnote b, expression of the HIS4-lacZ reporter on
plasmid M2296 in strain DY1143 (ace2 swi5) is given as a percentage normalized to the Swi5 control (line 2); footnote c, HO-lacZ expression (from
Fig. 2) is given as a percentage normalized to the Swi5 control (line 2); footnote d, CTS1-lacZ expression (from Fig. 2) is given as a percentage
normalized to the Ace2 control (line 1).
FIG. 5. Chimeras are expressed at
wild type levels. Western blotting was
used to determine protein levels of strains
with Swi5, Ace2, or various chimeras con-
taining a C-terminal Myc epitope tag.
Electrophoretic mobilities of the different
proteins are consistent with their pre-
dicted molecular masses. The cross-react-
ing material (C.R.M.) serves as a loading
control. Lane 1, DY150 with no epitope
tag; lanes 2–10, epitope tags were added
to wild type Swi5 in strain DY1142, wild
type Ace2 in strain DY150, and various
chimeras in strains DY4497 through
DY4503.
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chimeras activate expression to wild type levels. Thus activa-
tion of RME1 indicates a difference between the EF regions of
Swi5 and Ace2; the EF region of Ace2 stimulates transcrip-
tional activation better than the analogous region from Swi5.
CDC6—This gene shows a sharp dependence upon Swi5 for
activation, as CDC6 expression is reduced to similar extents in
swi5 single and swi5 ace2 double mutants (Fig. 8B). Expression
of CDC6 is also activated by the Swi4p/Swi6p complex and
Mcm1 (9, 28) and is probably responsible for the CDC6 expres-
sion remaining in the swi5 mutant. CDC6 is also the only gene
we have examined that shows a reproducible increase in acti-
vation in an ace2 strain (Table IV, line 3). The basis for this
increase is unclear but it is probably indirect.
The pattern of CDC6 activation by the chimeras is also
unique. The activating chimeras (lines 6, 7, 9, and 11) all
contain region EF of Swi5. For example, the ABCDSwi5EFAce2
chimera (line 5) is unable to activate CDC6, while the
ABCDAce2EFSwi5 chimera (line 6) activates CDC6 effectively.
This result is similar to that seen at SIC1 and PCL9, where
region EF of Swi5, containing the DNA-binding domain and
nuclear localization sequences for this protein, also contributes
to trans-activation. Region D of Swi5 is not a significant deter-
minant of CDC6 expression, unlike at SIC1, PCL9, and HO.
Unlike the situation at CDC6, region EF has no role in pro-
moter specificity at HO or CTS1.
DISCUSSION
The mechanisms that determine specific transcriptional ac-
tivation of genes are complex and often involve multiple fac-
tors. Domains within the transcription factor itself contribute
to promoter-specific activation by determining interactions
with specific proteins. We have examined transcriptional acti-
vation by the Swi5 and Ace2 transcription factors as a model
for promoter-specific activation in S. cerevisiae and have iden-
tified domains of these proteins that are required for transcrip-
tional activation of particular genes.
The Swi5 and Ace2 transcription factors have highly con-
served zinc finger DNA-binding domains, and they bind to
same DNA sequences in vitro (1). Nonetheless, these factors
activate different genes, with Swi5 activating HO expression
and Ace2 activating CTS1 (2). The Swi5 and Ace2 transcription
factors are cell cycle-regulated, being present in the nucleus for
a brief period in G1 of the cell cycle. Along with activating
transcription of HO and CTS1 in G1, it has been shown that
Swi5 and Ace2 contribute to the activation of a set of genes
expressed in G1, including ASH1, CDC6, EGT2, RME1, SIC1,
PCL2, and PCL9 (8–15). We have used the term “jointly” reg-
ulated when referring to these genes, as none of them shows a
strong requirement for only Swi5 or Ace2 as observed for HO
and CTS1. In order to determine what domains of Swi5 and
Ace2 contribute to the transcriptional activation of these vari-
ous G1 genes, we have constructed plasmids that express pro-
tein chimeras between Swi5 and Ace2. The analysis of tran-
scriptional activation of HO, CTS1, and the jointly regulated
genes by these fusion proteins allows us to identify specific
parts of the proteins required for promoter-specific activation.
Region D of Swi5 Is Necessary for Activation of HO—HO was
activated by any protein chimera containing region D (amino
acids 394–521) of Swi5, but not by chimeras lacking this region
(Figs. 2 and 6). Specific activation of HO requires region D of
Swi5, and this HO specificity region of Swi5 interacts in vitro
with the Pho2 homeodomain protein. In vitro experiments with
truncated derivatives of Swi5 demonstrated that amino acids
384–496 are required for cooperative DNA binding with Pho2
(25). A genetic screen has been performed to identify single
amino acid substitutions within this region that affect Swi5
activation of HO (26). Fifteen mutations between residues 482
and 505 of Swi5 were recovered, and many of these substitu-
tions also affect the ability of Swi5 to cooperatively bind DNA
with Pho2, without effecting HO expression (26). The genetic
analysis of these Swi5 point mutants suggests that this region
of Swi5 has two functions, activation of HO and interaction
with Pho2, and is consistent with a role for region D in specific
activation of HO.
Region C of Ace2 Is Necessary for Activation of CTS1—Anal-
ysis of the ability of the protein chimeras to activate CTS1
shows that region C (amino acids 303–469) of Ace2 is required
FIG. 6. Activation of HO and CTS1 by the Swi5/Ace2 chimeras.
S1 nuclease protection assays were performed using probes specific for
HO (A) and CTS1 (B), along with CMD1 as an internal control. RNAs
were prepared from the following strains: (A) DY150, DY411, DY1143,
DY4497, DY4498, DY4499, DY4500, DY4501, DY4502, and DY4503; (B)
DY150, DY1142, DY1143, DY4497, DY4498, DY4499, DY4500,
DY4501, DY4502, and DY4503.
TABLE IV
Relative contributions of Swi5 and Ace2 in activating early G1 genes
S1 nuclease protection assays were performed using probes specific
for each of the genes indicated, along with a CMD1 internal control in
each nuclease protection experiment. The experiment was performed
three times for all probes with three independent RNA preparations.
RNA levels were quantitated by PhosphorImager analysis, normalized
by dividing by the value for the CMD1 control, and values are given as
a percentage of wild type expression. Standard deviations were all less
than 40%; most were less than 20%. RNAs were prepared from the
following strains: DY150, DY411, DY1142, and DY1143.
Gene Wild type swi5 ace2 ace2 swi5
HO 100 1 60 1
CTS1 100 87 3 1
ASH1 100 88 92 33
CDC6 100 45 227 50
EGT2 100 80 92 1
PCL2 100 104 103 57
PCL9 100 36 101 18
RME1 100 75 52 11
SIC1 100 61 99 26
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(Figs. 2 and 6). Additionally, the ABSwi5CAce2DEFSwi5 chimera
shows that this CTS1 specificity region of Ace2 is sufficient for
CTS1-specific activation in the context of the Swi5 protein.
ABSwi5CAce2DEFSwi5 can activate both HO and CTS1, as it
contains region C of Ace2 and region D of Swi5 (Fig. 3). Region
C of the Ace2 protein contains a strong activation domain, as a
lexA-Ace2(region C) fusion is capable of activating transcrip-
tion of a reporter containing lexA sites in the promoter (data
not shown). Further experiments will be needed to determine
whether the general activation property of region C is neces-
sary for promoter-specific activation of CTS1, or whether the
two functions are separable.
Role of Region EF in Promoter-specific Activation—The pro-
tein chimeras demonstrated that the DNA-binding domains of
Swi5 and Ace2, present within region E, do not play a major
role in discrimination between HO and CTS1 (Figs. 2 and 6).
However, region EF, which includes the DNA-binding domain,
is important for activation of some of the jointly regulated
genes. The ABCDSwi5EFAce2 chimera activates RME1 better
than native Swi5 (Fig. 8), demonstrating that region EF of Ace2
contributes to activation. Analysis of the activation of SIC1 and
PCL9 by the chimeras shows that either region D or region EF
of Swi5 is required (Fig. 7). The fact that SIC1 and PCL9 are
effectively activated by the ABCDAce2EFSwi5 chimera, but
poorly by native Ace2, demonstrates a role for region EF of
Swi5. Finally, region EF of Swi5 is the only region required for
activation of CDC6 (Fig. 8). CDC6 is regulated by Swi5, and not
by Ace2, for at least part of its expression, making it most
similar to HO. However, unlike at HO, region D of Swi5 is not
critical for activation of CDC6; instead, region EF is important
for activation of CDC6. This difference may eventually provide
insight into promoter-specific activation by particular regions
of Swi5.
What are the functional domains in regions E and F? Region
E contains the DNA-binding domains of Swi5 and Ace2, and
region F contains sequences that control cytoplasmic retention
in G2 and nuclear localization in M and G1. Differences in Swi5
and Ace2 DNA binding at these promoters may play a role in
the strength of activation at SIC1, PCL9, RME1, and CDC6.
Interestingly, in vitro DNA-binding experiments conducted
with a SIC1 promoter probe show differences in binding by
Swi5 and Ace2 (12). Additionally, region F can be divided into
two parts. The first segment of 50 amino acids contains the
nuclear localization signals and is conserved between Swi5 and
Ace2 (48% identical, 94% similar), while the second segment of
30 amino acids is not conserved between Swi5 and Ace2. Fur-
ther work will be needed to establish whether it is the DNA-
binding domain in region E, the nuclear localization sequences
in region F, or some other function contained within these
regions that affects activation of RME1, SIC1, PCL9, and
CDC6.
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